These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 21031091)

  • 21. Transurethral Resection of Prostate and Bleeding: A Prospective, Randomized, Double-Blind Placebo-Controlled Trial to See the Efficacy of Short-Term Use of Finasteride and Dutasteride on Operative Blood Loss and Prostatic Microvessel Density.
    Bansal A; Arora A
    J Endourol; 2017 Sep; 31(9):910-917. PubMed ID: 28650680
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of 5α-reductase inhibitors for patients with large benign prostatic hyperplasia (>80 mL) after transurethral resection of the prostate.
    Qian X; Yu G; Qian Y; Xu D; Liu H; Kong X; Zhu Y; Wang Z; Zheng J; Qi J
    Aging Male; 2015; 18(4):238-43. PubMed ID: 26225794
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of Finasteride (5 alpha-reductase inhibitor) monotherapy in patients with benign prostatic hyperplasia: A critical review of the literature.
    Busetto GM; Del Giudice F; D'Agostino D; Romagnoli D; Minervini A; Rocco B; Antonelli A; Celia A; Schiavina R; Cindolo L; Chung BI; Kim JH; Maggi M; Sciarra A; De Berardinis E; Porreca A
    Arch Ital Urol Androl; 2020 Jan; 91(4):205-210. PubMed ID: 31937082
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Significance of intraprostatic architecture and regrowth velocity for considering discontinuation of dutasteride after combination therapy with an alpha blocker: a prospective, pilot study.
    Shindo T; Hashimoto K; Shimizu T; Itoh N; Masumori N
    Korean J Urol; 2015 Apr; 56(4):305-9. PubMed ID: 25874044
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of finasteride on prostate volume and prostate-specific antigen.
    Chiu KY; Yong CR
    J Chin Med Assoc; 2004 Nov; 67(11):571-4. PubMed ID: 15720071
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost effectiveness comparison of dutasteride and finasteride in patients with benign prostatic hyperplasia--The Markov model based on data from Montenegro.
    Dabanović V; Kostić M; Janković S
    Vojnosanit Pregl; 2016 Jan; 73(1):26-33. PubMed ID: 26964381
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Changes in the Serum Prostatic Biomarkers During the Treatment of Benign Prostatic Hyperplasia with a 5alpha-reductase Inhibitor: Finasteride.
    Golchin-Rad K; Mogheiseh A; Nazifi S; Ahrari Khafi MS; Derakhshandeh N; Abbaszadeh-Hasiri M
    Top Companion Anim Med; 2020 Mar; 38():100405. PubMed ID: 32115076
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Change in Prostate Specific Antigen Concentration in Men with Prostate Specific Antigen Less than 2.5 ng/ml Taking Low Dose Finasteride or Dutasteride for Male Androgenetic Alopecia.
    Kang HW; Chae MH; Park SH; Seo SP; Kim WT; Kim YJ; Yun SJ; Lee SC; Yoon TY; Kim WJ
    J Urol; 2017 Dec; 198(6):1340-1345. PubMed ID: 28743526
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dutasteride, who is it more effective for? Second to fourth digit ratio and the relationship with prostate volume reduction by dutasteride treatment.
    Kim TB; Oh JK; Kim KH; Jung H; Yoon SJ; Lee MS; Kim SW
    BJU Int; 2012 Dec; 110(11 Pt C):E857-63. PubMed ID: 22755506
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sexual dysfunction in subjects treated with inhibitors of 5α-reductase for benign prostatic hyperplasia: a comprehensive review and meta-analysis.
    Corona G; Tirabassi G; Santi D; Maseroli E; Gacci M; Dicuio M; Sforza A; Mannucci E; Maggi M
    Andrology; 2017 Jul; 5(4):671-678. PubMed ID: 28453908
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical effects and economical impact of dutasteride and finasteride therapy in Italian men with LUTS.
    Cindolo L; Berardinelli F; Fanizza C; Romero M; Pirozzi L; Tamburro FR; Pellegrini F; Neri F; Pitrelli A; Schips L
    Arch Ital Urol Androl; 2013 Dec; 85(4):200-6. PubMed ID: 24399122
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical usefulness of serum prostate specific antigen for the detection of prostate cancer is preserved in men receiving the dual 5alpha-reductase inhibitor dutasteride.
    Andriole GL; Marberger M; Roehrborn CG
    J Urol; 2006 May; 175(5):1657-62. PubMed ID: 16600723
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Consequences of switching 5alpha-reductase inhibitors on prostate specific antigen velocity.
    Helfand BT; Blackwell RH; McVary KT
    J Urol; 2010 Jul; 184(1):218-23. PubMed ID: 20483154
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of treatment with statins on prostate-specific antigen and prostate volume in patients with benign prostatic hyperplasia.
    Lee SH; Park TJ; Bae MH; Choi SH; Cho YS; Joo KJ; Kwon CH; Park HJ
    Korean J Urol; 2013 Nov; 54(11):750-5. PubMed ID: 24255756
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Therapeutic effects of finasteride in benign prostatic hyperplasia: a randomized double-blind controlled trial.
    Yu HJ; Chiu TY; Lai MK
    J Formos Med Assoc; 1995; 94(1-2):37-41. PubMed ID: 7542109
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serum prostate-specific antigen and prostate volume predict long-term changes in symptoms and flow rate: results of a four-year, randomized trial comparing finasteride versus placebo. PLESS Study Group.
    Roehrborn CG; Boyle P; Bergner D; Gray T; Gittelman M; Shown T; Melman A; Bracken RB; deVere White R; Taylor A; Wang D; Waldstreicher J
    Urology; 1999 Oct; 54(4):662-9. PubMed ID: 10510925
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia.
    Bartsch G; Rittmaster RS; Klocker H
    World J Urol; 2002 Apr; 19(6):413-25. PubMed ID: 12022710
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of Additional Dutasteride on Lower Urinary Tract Symptoms in Patients with Alpha-1 Blocker-Resistant Benign Prostatic Hyperplasia.
    Sengiku A; Miyazaki Y; Sawazaki H; Takahashi T; Ogura K
    Low Urin Tract Symptoms; 2013 Sep; 5(3):159-63. PubMed ID: 26663453
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lack of correlation between prostate-specific antigen density and prostatic shrinkage in response to finasteride therapy.
    Kirschenbaum A; Pacheco E; Schuval BJ; Levine AC
    World J Urol; 1996; 14(6):360-2. PubMed ID: 8986036
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of dutasteride on prostate biopsy rates and the diagnosis of prostate cancer in men with lower urinary tract symptoms and enlarged prostates in the Combination of Avodart and Tamsulosin trial.
    Roehrborn CG; Andriole GL; Wilson TH; Castro R; Rittmaster RS
    Eur Urol; 2011 Feb; 59(2):244-9. PubMed ID: 21093145
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.